CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Decitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02109744
NCT02109744Phase 2Completed
CompareCT.gov

A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

University of Rochester·interventional·Posted Apr 10, 2014·Updated Jul 5, 2022

In Brief

A Phase 2 clinical trial evaluating Decitabine for Acute Myelogenous Leukemia. Completed, enrolled 27 participants across 1 site.

Detailed Summary

To evaluate the response to chemotherapy with the drug decitabine combined with rapamycin in the treatment of relapsed or refractory acute myeloid leukemia in patients of all ages, and in the treatment of newly diagnosed leukemia in those who are older than 65 when diagnosed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 10, 2014
Enrollment StartMar 1, 2014
Primary CompletionJan 1, 2022
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 12.2 years ago

Interventions

Decitabinedrug